CADTH recommends that Vraylar should be reimbursed by public drug plans for the treatment of schizophrenia in adults if certain conditions are met.
CADTH recommends that Vraylar should be reimbursed by public drug plans for the treatment of schizophrenia in adults if certain conditions are met.